Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in Transthyretin Amyloid Polyneuropathy (V30M and non-V30M)
jRCT2080221636Phase 3
- Sponsor
- Pfizer
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafamidis in familial amyloid polyneuropathy (FAP), sponsored by Pfizer. Primary endpoints: Transthyretin stabilization and Safety and tolerability.
02
Drugs
tafamidis
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on jRCT2080221636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221636.